Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?

Reviewed 18 sourcesPublished by PepVault

Most people no longer stop a GLP-1 before surgery. What the labels, the 2024 multi-society guidance and the 2025 SPAQI consensus say, and when to restart.

Man in a mustard tee unpacks folded clothes from a grey suitcase on a hotel bed, fruit and a palm on the side table
Last reviewed
Sources
18
Questions
7
Compounds
2

The short answer

As of November 2026, most people do not stop. The 2024 multi-society guidance and the 2025 SPAQI consensus keep most patients on their weekly shot and protect the stomach instead, often with a clear-liquid day before anesthesia. A hold, usually a week, is kept for some higher-risk cases. Tell your surgical team the drug, the dose and your last shot day, and follow their plan.

Every number checked at its primary source · · 18 sources · How we research

Evidence: Guidance and consensus, not trials: the four FDA labels, the ASA 2023 consensus, the 2024 multi-society guidance and the 2025 SPAQI Delphi consensus; behind them, observational studies in people (gastric ultrasound and endoscopy studies of food left in the stomach, and two large database studies of aspiration and breathing complications). There are no randomised trials on stopping or continuing.

Man in a mustard tee unpacks folded clothes from a grey suitcase on a hotel bed, fruit and a palm on the side table

Why does a GLP-1 matter for anesthesia?

Because these drugs slow the stomach. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) delay gastric emptying, the speed at which food leaves the stomach1234. Under general anesthesia or deep sedation the reflexes that guard the airway are off, so food left in the stomach can come up and be breathed into the lungs. That is pulmonary aspiration.

All four US labels carry the same warning: Wegovy and Ozempic in section 5.10, Mounjaro and Zepbound in 5.9. It reports "rare postmarketing reports" of aspiration in people who had food left in the stomach "despite reported adherence to preoperative fasting recommendations", says the data are insufficient to tell whether a changed fast or a pause would lower the risk, and gives one instruction: tell your providers before any planned procedure that you take the drug1234.

The effect fades. The tirzepatide labels say the delay is largest after the first dose and shrinks over time34, and the 2023 anesthesia guidance noted the same with long-term use5. So the newer guidance looks hardest at people who have just started or stepped up a dose.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault logs each shot on its day with the dose you took, and its Doctor's report lists each compound's current dose and schedule, so your last shot day and dose are on your phone when the pre-op nurse asks.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What did the studies find in the stomach?

Most studies looked straight into the stomach, with the endoscope or with a quick ultrasound scan (gastric ultrasound) just before anesthesia, in people who had fasted by the usual rules.

StudyWhoStomach not empty (food or extra fluid): on the drugNot on the drug
Silveira 2023, endoscopy records404 adults, 33 of them on semaglutide in the past 30 days24.2%5.1%10
Sen 2024, gastric ultrasound124 adults, half on weekly GLP-1 drugs56%19%11
Nersessian 2024, gastric ultrasound220 adults, 107 on semaglutide in the past 10 days40%3%12
Vlaeminck 2026, gastric ultrasound, matched for age, weight and diabetes88 adults, 44 on semaglutide49%18%13
Boudreau 2026, gastric ultrasound, drug held at least 7 days93 adults, weekly GLP-1 drugs42%24% (not statistically significant; the study was small)14

Food in the stomach is a risk factor, not an aspiration, and counts of actual aspiration are calmer. In a BMJ study of 43,365 adults with type 2 diabetes having an upper endoscopy, aspiration happened in 4.15 per 1,000 GLP-1 users and 4.26 per 1,000 users of another diabetes drug class; the endoscopy was stopped more often on a GLP-1, 9.79 against 4.91 per 1,000, possibly because of food in the stomach17. In 23,679 people with diabetes having emergency surgery, too soon to hold any drug, breathing complications were 3.5% with a GLP-1 and 4.0% without, no difference after adjustment18.

Aspiration is rare in any surgery, 0.02% to 0.07% of patients by SPAQI's count7, so even large studies struggle to show a difference. The societies act on the fuller stomach and plan for it.

What changed from the 2023 advice to now?

In June 2023 the American Society of Anesthesiologists (ASA) told everyone on a weekly GLP-1 to consider holding it for a week before an elective procedure, whatever the reason for taking it, the dose or the surgery5. Since then the advice has turned. A 2026 review of the five main guidance documents published since 2023 found that four of them now keep the drug going and change the fast instead, replacing the 2023 hold-for-everyone policy8. The ASA's own page for patients, reviewed in October 2025, says most patients can keep taking the drug as usual9.

PointASA, June 2023Multi-society, October 2024SPAQI, 2025
Who wrote itThe ASA's fasting task force5ASA, AGA, ASMBS, ISPCOP and SAGES: the anesthesia, gut, obesity-surgery, obesity-care and endoscopic-surgery societies6SPAQI, a perioperative-medicine society, after a systematic review7
Keep taking it?Consider holding: daily drugs on the day, weekly drugs for a week5Yes, unless the risk factors below are present; decided together by you, the surgical, anesthesia and prescribing teams6Yes, unless you have significant stomach symptoms7
If it is heldA week for weekly shots5The right length is unknown; a week for weekly, the day of for daily6Not held without significant symptoms; those go back to the prescriber first7
Food and drink beforeThe usual ASA fasting rules5A liquid diet for at least 24 hours when there is concern6Clear liquids only for 24 hours; sugary clear drinks stop 8 hours before, low-sugar ones 4 hours before7
On the daySymptoms: consider delaying; not held: treat as a full stomach or scan it5Ask about symptoms; scan if in doubt; adjust the anesthetic or reschedule6A scan for people with symptoms or who skipped the diet7
RestartingNot covered5Not covered6When you are back on your usual diet7

The multi-society document's reasons not to stop everyone: a pause can push blood sugar up in diabetes, bridging to another drug costs money and brings risks such as low blood sugar, and holding a drug only because someone has obesity would be obesity bias6. It calls itself guidance, not an evidence-based guideline, built on pharmacology and clinical experience6.

Who is at higher risk of a full stomach?

The multi-society guidance names five things that raise the chance of a slow stomach on the day6:

  • The escalation phase, the weeks of stepping up to the full dose, more than the steady maintenance phase.
  • A higher dose.
  • A weekly drug rather than a daily one.
  • Stomach symptoms: nausea, vomiting, stomach pain, indigestion or constipation.
  • Other conditions that slow the gut, such as gastroparesis or Parkinson's disease.

The ASA's patient page adds timing: escalation usually lasts four to eight weeks, and for a planned operation it is best to wait until it is over9. SPAQI draws its line at significant symptoms, meaning severe nausea, vomiting or being unable to keep food down, not fullness7.

When to get help If you have nausea, vomiting, bloating or stomach pain in the days before a procedure, call the surgical team before you come in; all three guidances treat these as a reason to change the plan567.

Does holding the shot for a week empty the stomach?

Not reliably. The reason is the half-life, the time it takes for half the drug to leave the blood. Semaglutide's is about one week, and it stays in circulation for about 5 to 7 weeks after the last shot1; tirzepatide's is about 5 days, 5 to 6 in people with obesity34. So a week after the last shot about half the semaglutide is still there, and about 40% of the tirzepatide. The chart shows how tirzepatide builds up and falls on a weekly schedule.

Try it

How Tirzepatide builds up

An estimate from a half-life of about 5 days, one dose a week for four weeks. The shape of the level, not a measurement.

Try your own scheduleTirzepatide in the library

The studies agree. In Sen's study the length of the break made no difference11; in Silveira's, people with and without food left had stopped semaglutide for about the same time, 10.5 and 10.2 days on average10; in Boudreau's, 42% still had food after a hold of at least a week14. A Mayo Clinic study of 316 people linked holds of 7.5 days or less to fuller stomachs, and also solid-food fasts of 21.3 hours or less15. A Detroit study of 337 endoscopies found that fasting from solids for more than 15 hours cut the odds of food in the stomach by about two-thirds, while a hold of under a week made no clear difference16. In both, a longer solid-food fast went with an emptier stomach, and a fast costs no weeks of treatment.

What should you tell your surgical team?

The labels' one instruction is to tell them1234, and every guidance builds its plan from what you say. Do it at booking or the pre-operative call, not on the morning, because a liquid-diet day has to start earlier6.

  1. Name the drug and the brand: Ozempic, Wegovy (shot or tablet), Mounjaro, Zepbound or another.
  2. Give the dose you are on now, and say whether you are still stepping up or have been on the same dose for a while.
  3. Give your last shot day and your usual shot day, so they can see where the operation falls in your week.
  4. Mention any nausea, vomiting, bloating, stomach pain or constipation, even if it is mild.
  5. If you take it for diabetes, say so and list your other diabetes medicines, since a pause may need a plan for blood sugar56.
  6. Ask who decides whether to keep or hold the dose: the guidance makes it a shared decision between you and the surgical, anesthesia and prescribing teams6.
  7. Follow the fasting instructions you are given to the hour, including a clear-liquid day if they ask for one.

PepVault logs each shot on its day with the dose you took, and its Doctor's report lists each compound's current dose and schedule, so your last shot day and dose are on your phone when the pre-op nurse asks. Log it in PepVault

Commonly reported: one clinic saying stop a week ahead and another saying keep going, as hospitals moved to the newer guidance at different speeds; and the clear-liquid day feeling easier than expected, because appetite is already low.

When do you restart a GLP-1 after surgery?

Only the SPAQI consensus answers it: restart once you are back on your usual diet, at home (grade B) or in hospital (grade E, expert opinion)7. It warns that stopping can bring the stomach side effects back on restart7. The 2023 ASA advice and the 2024 multi-society guidance do not cover restarting56.

Under the labels a held dose is a missed dose, and each label sets its own window for a late shot1234; the missed-dose tool at pepvault.app/tools/missed-glp1-dose quotes each one. A hold plus a slow recovery can trigger one more Wegovy rule: after two or more missed weekly doses in a row, the climb restarts at a lower dose1. The restart dose is your prescriber's call.

Every logged shot keeps its date in PepVault, so the last shot before the break is in your history when you and your prescriber plan the restart. Log it in PepVault

Track it in the app

Sources

  1. Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information, §2.4, §5.10, §12.2, §12.3 and Medication Guide. DailyMed, SPL version 19, June 30, 2026. dailymed.nlm.nih.gov
  2. Novo Nordisk. OZEMPIC (semaglutide) injection, prescribing information, §2.1, §5.10 and Medication Guide. DailyMed, SPL version 20, June 10, 2026. dailymed.nlm.nih.gov
  3. Eli Lilly and Company. MOUNJARO (tirzepatide) injection, prescribing information, §2.1, §5.9, §10, §12.2, §12.3 and Medication Guide. DailyMed, SPL version 40, September 2, 2026. dailymed.nlm.nih.gov
  4. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information, §2.3, §5.9, §12.2, §12.3 and Medication Guide. DailyMed, SPL version 40 (published September 2, 2026; revised August 2026). dailymed.nlm.nih.gov
  5. Joshi GP, Abdelmalak BB, Weigel WA, et al.; ASA Task Force on Preoperative Fasting. American Society of Anesthesiologists consensus-based guidance on preoperative management of patients (adults and children) on glucagon-like peptide-1 (GLP-1) receptor agonists. ASA, June 29, 2023. asahq.org
  6. Kindel TL et al.; AGA, ASMBS, ASA, ISPCOP and SAGES. Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surg Endosc. 2025 (online October 2024). PubMed 39370500
  7. Oprea AD et al. Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement. Br J Anaesth. 2025. PubMed 40379536
  8. Moore T, Ramsahoye B. Perioperative management of patients taking GLP-1 receptor agonists: a comparative review of international clinical guidelines. Saudi J Anaesth. 2026. PubMed 42960088
  9. American Society of Anesthesiologists, Made for This Moment. Drugs for diabetes and weight loss (patient page), medically reviewed October 22, 2025. madeforthismoment.asahq.org
  10. Silveira SQ et al. Relationship between perioperative semaglutide use and residual gastric content: a retrospective analysis of patients undergoing elective upper endoscopy. J Clin Anesth. 2023. PubMed 36870274
  11. Sen S et al. Glucagon-like peptide-1 receptor agonist use and residual gastric content before anesthesia. JAMA Surg. 2024. PubMed 38446466
  12. Nersessian RSF et al. Relationship between residual gastric content and peri-operative semaglutide use assessed by gastric ultrasound: a prospective observational study. Anaesthesia. 2024. PubMed 39435967
  13. Vlaeminck N et al. Gastric ultrasound in patients receiving semaglutide: a prospective, multicentre, matched control study. Anaesthesia. 2026. PubMed 41631344
  14. Boudreau C et al. Residual gastric content after holding of glucagon-like peptide-1 receptor agonists before elective surgery: a cross-sectional study (the RESIDUAL study). BMC Anesthesiol. 2026. PubMed 42265610
  15. Pai SL et al.; MAGIC Collaborators. Assessment of gastric content using gastric ultrasound in patients on glucagon-like peptide-1 receptor agonists before anesthesia. Anesth Analg. 2026. PubMed 41032460
  16. Mendez-Pino L et al. Preoperative fasting status and retained gastric contents in patients undergoing endoscopy who are using glucagon-like peptide type 1 receptor agonists: a multicentre retrospective study. Can J Anaesth. 2026. PubMed 42618722
  17. Alkabbani W et al. Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study. BMJ. 2024. PubMed 39438043
  18. Dixit AA et al. Preoperative GLP-1 receptor agonist use and risk of postoperative respiratory complications. JAMA. 2024. PubMed 38648036

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo